Medicine and Health
Clinical trials are currently underway in the United States to test the efficacy of HIV PrEP injections that only need to be administered every 6 months
Trials for a novel variant of extended-release pre-exposure prophylaxis (PrEP), a preventive treatment for HIV, have commenced in the United States. In addition to potentially providing a new approach for HIV prevention, the trials are specifically targeting two marginalized populations that have historically been neglected in HIV research: cisgender women and individuals who engage in injectable drug use.
The implementation of PrEP marked a significant advancement in the ongoing battle against HIV. When used in accordance with medical instructions, it decreases the likelihood of acquiring HIV through sexual intercourse by 99 percent and through intravenous drug use by 74 percent.
PrEP typically consists of a daily pill regimen to ensure optimal protection. In 2021, the Food and Drug Administration (FDA) granted approval for an injectable version of PrEP that is administered every two months. However, this form of PrEP is not yet widely accessible.
The ongoing clinical trials are testing a novel form of PrEP designed to be administered every six months, aiming to enhance convenience and accessibility for certain individuals. The treatment utilizes lenacapavir, an FDA-approved drug specifically designed for managing HIV that is resistant to conventional therapies.
The University of California San Diego Antiviral Research Center is currently running trials that are actively recruiting people from two groups that have not been adequately represented in HIV research in the past: cisgender women (people whose biological sex is female and whose gender identity corresponds to this), with a focus on black and Latina participants; and people who currently inject drugs, such as opioids and cocaine.
According to a statement from the National Institutes of Health (NIH), these populations represent 18 percent and 7 percent of new HIV diagnoses in the US, respectively. According to HIV.gov, 70 percent of newly acquired HIV infections in 2021 were among men who engaged in sexual activity with other men. However, there has been an increase in demand in recent years for trials and investigations to include a wider range of people affected by this virus.
The studies will be conducted at various locations throughout the United States, enrolling individuals who meet the specified criteria for inclusion and who could potentially derive advantages from using PrEP. Participants will be assigned at random to receive either the new lenacapavir injections or an oral PrEP formulation that has already been approved for use. The researchers will prioritize the examination of safety, the mechanism of action of the drug within the body, and the assessment of potential side effects experienced by the participants.
The prognosis for individuals recently diagnosed with HIV has significantly improved over the past five decades. The promotion of safe sexual practices has significantly contributed to preventing infection in numerous individuals. Furthermore, advancements in antiretroviral treatments have made it feasible for many individuals to achieve an undetectable viral load, thereby eliminating the risk of transmitting the infection. The recent implementation of PrEP provided individuals at risk with an additional means of safeguarding themselves against infection.
It will take a considerable amount of time before we observe any outcomes from these trials. However, if they prove to be successful, it could introduce a more easily attainable method of preventing HIV infection. Additionally, it would enhance our scientific understanding of marginalized groups, who are frequently overlooked in discussions.
Medicine and Health
A recently identified strain of deadly fungus poses a significant risk to public health
Researchers have recently discovered a new group of Candida auris, a potentially dangerous pathogen. The finding increases the total number of identified clades of the fungus, which is a newly emerging superbug resistant to multiple drugs, to six.
Candida auris is a strain of yeast that has the potential to cause serious illness and is frequently impervious to antifungal drugs. While individuals who are in good health generally do not fall ill, the transmission of the disease is highly prevalent within medical institutions and poses a significant risk to individuals with compromised immune systems. The yeast can induce a variety of conditions ranging from superficial infections of the skin to more severe and life-threatening illnesses, such as bloodstream infections. Due to its high level of resistance to multiple drugs, treating it can be challenging, and in some cases, even impossible.
The authors state that the pathogen is a significant global public health threat due to its widespread distribution, resistance to multiple drugs, high ability to spread, tendency to cause outbreaks, and high mortality rate. Although infections are still relatively uncommon, there has been a significant increase in cases in recent years.
Previously, the fungus had been categorized into five distinct clades, each located in different geographic regions: South Asia, East Asia, Africa, South America, and Iran.
In April 2023, doctors from the Singapore General Hospital identified a patient carrying a unique strain of C. auris as part of a routine screening program, adding it as the most recent clade to be discovered. Typically, these cases arise from individuals who have recently traveled, but this particular patient had not traveled outside the country for a period of two years, which raised some concerns.
Upon conducting a genetic analysis of the strain, the researchers determined that it did not align with any of the five known clades of the fungus. Therefore, it can be concluded that the strain belongs to a previously unidentified, sixth clade. Subsequently, they conducted tests on strains obtained from previous patients and identified two additional isolates of this particular group of C. auris in Singapore, as well as another isolate in Bangladesh.
The extent of the new clade’s prevalence and its potential to cause invasive infections and outbreaks remains uncertain at present. However, the researchers emphasize the importance of promptly identifying and controlling it in order to safeguard patient well-being.
“The ramifications of this breakthrough transcend the confines of the laboratory.” “Given the recent discovery of the sixth Candida auris clade, it is imperative to enhance surveillance capability or create new methods to strengthen existing surveillance strategies. This will enable health care facilities to closely monitor its emergence and effectively control its spread,” stated Dr. Karrie Ko, co-first author of the study.
Fortunately, the cases described in the study remained vulnerable to all antifungals that were tested. This should alleviate concerns about a pandemic similar to the one depicted in The Last Of Us. However, it is evident that the threat of C. auris is persistent. Therefore, additional efforts are required to identify new strains, monitor their spread, and control any negative clinical consequences.
The research is published in The Lancet Microbe journal.
Medicine and Health
What makes your chest hurt when something makes you jump?
Have you ever been scared so badly that you grabbed your chest? You feel like someone or something just zapped you behind the sternum. As you rest, you lean against the wall and think about why your friend is such a jerk and why you can feel it in your chest whenever you get scared.
People often use words like “heart-stopping” when they write fiction about fear, but the science of fear tells us that this isn’t what’s happening because it wouldn’t make sense. Our bodies are getting ready to deal with an impending threat when we’re scared, and going into cardiac arrest wouldn’t help us get very far if a lion was after us.
What do we do when we’re scared?
The sympathetic nervous system is what gets you excited when something makes you jump. It’s a tool inside our bodies that releases hormones and changes the way our bodies work to get us ready for the fight-or-flight response.
One important part is adrenaline, which is also known as epinephrine. The adrenal glands squeeze it out into the blood. The heart starts beating faster, sending more blood to your muscles and organs right away. Because they need all the oxygen they can get if they want to get away from a dangerous animal.
How do you feel when you go for a run?
Anyone who has ever used an EpiPen knows how bad it is to feel a sudden rush of adrenaline. It’s a stress hormone that makes you feel nervous and anxious, like you would before doing a bungee jump. Getting a rush when you think about a traumatic event from the past can be a sign of PTSD.
A medicine called adrenaline is used because it can help people who are having a medical emergency. If you have anaphylaxis from an allergen like peanuts, this can help because it can open your airway. Because it changes the strength and speed of heartbeats, it is also sometimes used to help people who are having a cardiac arrest.
When your adrenaline level goes up quickly, you may feel shaky, your heart beat quickly, and your chest get tight. When you add in the fact that you’re more alert, you become very aware of the changes in your body. This is especially clear when you’re not in danger, like when your partner surprised you at home when you thought you were alone.
When you’re scared, your sympathetic nervous system usually kicks in, which is normal. But, some heart conditions can get worse when you’re scared. Should anyone be having chest pain or ongoing discomfort, they should see a doctor. In the end, it is possible to be so scared that you die.
This article is not meant to be a replacement for medical advice, diagnosis, or treatment from a trained professional. If you have questions about a medical condition, you should always talk to a qualified health professional.
Medicine and Health
The Lacks family is suing again over her “stolen” cells
The family of Henrietta Lacks has filed a new lawsuit against two sizable drug companies for using her genetic material without her consent.
In the US District Court for the District of Maryland, Lacks’ living relatives are suing Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc., Viatris, Inc., and its subsidiary, Mylan Pharmaceuticals. They say the companies have used the “stolen” HeLa cell line to make hundreds of patents and have made a lot of money from it.
The suit wants the money made from using these cells to be “rightfully transferred” to Henrietta Lacks’s estate.
Novartis and Viatris chose to sell Henrietta Lacks’ living genetic material. Lacks was a black grandmother, community leader, and woman whose doctors took her tissue without her knowledge or permission, according to Chris Ayers, an attorney at Seeger Weiss LLP who is representing the Lacks family.
Ayers added, “We will keep looking for justice for Mrs. Lacks and her family.”
Henrietta Lacks died on October 4, 1951, from cervical cancer. She was 31 years old. Some of her cells are still alive today. A doctor at Johns Hopkins Hospital took a sample of her cervical cells without her knowledge just before she died. They were doing a cancer check. It was seen that her cells kept multiplying quickly, even after most of the cells in other samples would have died without their host.
Because scientists saw the potential, they found that these cells could be a cheap and easy way to help researchers do more research. The “HeLa immortal cell line” is what scientists call these cells, and they are very useful for biomedical research.
Over 75,000 scientific studies around the world have used these cells, which amount to about 55 million tons. They have been very important in making progress in areas like polio vaccines, cancer treatments, HIV/AIDS treatments, and much more.
All of this was done, though, without Lacks’ knowledge or permission. For many years, her family also didn’t know that the cells were being used for business.
Selling HeLa cells for money brings up important issues in medical ethics and genetics. As a black woman living in America in the 1950s, Lacks’ case shows how medical racism still affects minorities who aren’t getting enough help.
Even though a lot of people know about these problems, HeLa cells are still used in medical research for profit, which makes some companies a lot of money.
“Now that everyone knows Henrietta Lacks’ story, it’s shocking, but not surprising, that drug companies like Novartis and Viatris are still making money off of the deeply unethical origins of HeLa cells and the disturbing history of medical racism,” said Chris Seeger, another lawyer for the family.
A historic deal was made by Lacks’ family in 2023 after they sued Thermo Fisher Scientific, Inc., another biotech company, in the US District Court for the District of Baltimore. During that time, the lawyers said that the settlement was only the beginning and that there could be many more lawsuits about the use of HeLa cells.
- Gadgets10 years ago
Why the Nexus 7 is still a good tablet in 2015
- Mobile Devices10 years ago
Samsung Galaxy Note 4 vs Galaxy Note 5: is there room for improvement?
- Editorials10 years ago
Samsung Galaxy Note 4 – How bad updates prevent people from enjoying their phones
- Mobile Devices9 years ago
Nexus 5 2015 and Android M born to be together
- Gaming10 years ago
New Teaser For Five Nights At Freddy’s 4
- Mobile Devices9 years ago
Google not releasing Android M to Nexus 7
- Gadgets10 years ago
Moto G Android 5.0.2 Lollipop still has a memory leak bug
- Mobile Devices9 years ago
Nexus 7 2015: Huawei and Google changing the game